Luteolin Inhibits Proliferation Induced by IGF-1 Pathway Dependent ERα in Human Breast Cancer MCF-7 Cells |
Wang, Li-Meng
(Liaoning Provincial Key Laboratory of Biotechnology and Drug Discover, College of Life Science, Liaoning Normal University)
Xie, Kun-Peng (Liaoning Provincial Key Laboratory of Biotechnology and Drug Discover, College of Life Science, Liaoning Normal University) Huo, Hong-Nan (Liaoning Provincial Key Laboratory of Biotechnology and Drug Discover, College of Life Science, Liaoning Normal University) Shang, Fei (Liaoning Provincial Key Laboratory of Biotechnology and Drug Discover, College of Life Science, Liaoning Normal University) Zou, Wei (Liaoning Provincial Key Laboratory of Biotechnology and Drug Discover, College of Life Science, Liaoning Normal University) Xie, Ming-Jie (Liaoning Provincial Key Laboratory of Biotechnology and Drug Discover, College of Life Science, Liaoning Normal University) |
1 | Klotz DM, Hewitt SC, Ciana P, et al (2002). Requirement of estrogen receptor-alpha in insulin-like growth factor-1(IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem, 277, 8531-7. DOI |
2 | Law JH, Habibi G, Hu K, et al (2008). Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res, 68, 10238-46. DOI |
3 | Lin Y, Shi R, Wang X, et al (2008). Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets, 8, 634-46. DOI |
4 |
Oesterreich S, Zhang P, Guler RL, et al (2001). Re-expression of estrogen receptor |
5 | Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28. DOI ScienceOn |
6 | Ren WY, Qiao ZH, Wang HW, et al (2003). Flavonoids: Promising AnticancerAgents. Med Res Rev, 23, 519-34. DOI ScienceOn |
7 | Resnicoff M, Abraham D, Yutanawiboonchai W, et al (1995). The insulin-like growth factor 1 receptor protects tumor cells from apoptosis in vivo. Cancer Res, 55, 2463-9. |
8 | Sachdev D, Yee D (2001). The IGF system and breast cancer. Endocrine-Related Cancer, 8, 197-209. Sachdev D, Yee D (2001). The IGF system and breast cancer. Endocr Relat Cancer, 8, 197-209. DOI ScienceOn |
9 | Sachdev D, Yee D (2007). Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther, 6, 1-12. |
10 | Salerno M, Sisci D, Mauro L, et al (1999). Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer, 81, 299-304. DOI |
11 | Sarfstein R, Pasmanik-Chor M, Yeheskel A, et al (2012). The insulin-like growth factor-I receptor (IGF-IR) translocates to the nucleus and autoregulates IGF-1R gene expression in breast cancer cells. J Biol Chem, 287, 2766-76. DOI |
12 | Sogno I, Vene R, Ferrari N, et al (2010)., Angioprevention with fenretinide: targeting angiogenesis in preventiion and therapeutic strategies. Crit Rev Oncol Hematol, 75, 2-14. DOI |
13 | Surmacz E (2002). Function of the IGF-1 receptor in breast cancer. J Mammary Glnad Biol Neoplasia, 5, 95. |
14 | Surmacz E, Bartucci M (2004). Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res, 23, 385-94. |
15 | Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Trtosa MC, et al (2011). Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit Rev Oncol Heamtol, 80, 347-68. DOI ScienceOn |
16 | Wang ZF, Cui MB, Song FR, et al (2008). Evaluation of flavonoids binding to DNA duplexes by electrospray ionization mass spectrometry. J Am Soc Mass Spectrom, 19, 914-22. DOI |
17 | Werner H, LeRoith D (2000). New concepts in regulation of the insulin-like growth factors: implication for understanding normal growth and neoplasia. Cell Mol, 57, 932-42. DOI |
18 | Weroha SJ, Haluska P (2008). IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol, 13, 471-83. DOI |
19 | Yuen JS, Macaulay VM (2008). Targeting the type 1 inslin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets, 12, 589-603. DOI |
20 | Xia Y, Jin L, Zhang B, et al (2007). The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci, 80, 2161-9. DOI |
21 | Zha J, O'Brien C, Savage H, et al (2009). Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther, 8, 2110-21. DOI |
22 |
Zhang S, Li X, Burghardt R, et al (2005). Role of estrogen receptor(ER |
23 | Zhu C, Qi X, Chen Y, et al (2011). PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol, 137, 1587-94. DOI |
24 | Buck E, Gokhale PC, Koujak S, et al (2010). Compensatory insulin receptor (IR) activatio on inhibition of insulin-like growth factor-1 receptor(IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther, 9, 2652-64. DOI |
25 | Baselga J, Campone M, Piccart M, et al (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 366, 520-9. DOI ScienceOn |
26 | Basela J, Cortes J, Kim SB, et al (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 366, 109-19. DOI |
27 | Baserga R (2009). Customizing the targeting of IGF-1 receptor. Future Oncol, 5, 43-50. DOI |
28 | Bustin SA, Dorudi S, Phillips SM, et al (2002). Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumor Biol, 23, 130-8. DOI |
29 | Berrino F, De AR, Sant M, et al (2007). Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol, 8, 773-83. DOI |
30 | Buck E, Mulvihill M (2011). Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investing, 20, 605-21. DOI |
31 | Castoria G, Migliaccio A, Bilancio A, et al (2001). PI3-kinase in concert with Src promotes the S-phase entry of estradiol-stimulated MCF-7 cells. EMBO J, 20, 6050-9. DOI |
32 | Carboni JM, Lee AV, Had sell DL, et al (2007). Tumor development by transgenic expression of a constitutively active insulin - like growth factor I receptor. Cancer Res, 65, 3781-7. |
33 | Dong RY, Yun HJ, Yeong KJ, et al (2009). Proteomic identification of anti-cancer proteins in luteolin-treated human hepatoma Huh-7 cells. Cancer Lett, 282, 48-54. DOI |
34 | Fang J, Zhou Q, Shi XL, et al (2007). Luteolin inhibits insulinlike growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis, 28, 713-23. |
35 | Dong S, Akio I, Yun Z, et al (2007). Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of Glycyrrhiza glabra root. Food Chem Toxicol, 45, 2470-8. DOI |
36 | Du GJ, Song ZH, Lin HH, et al (2008). Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells. Biochem Biophys Res Commun, 372, 497-502. DOI |
37 | Fagan DH, Yee D (2008). Crosstalk between IGFIR and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia, 13, 423-9. DOI |
38 | Gualberto A, Pollak M (2009). Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets, 10, 923-36. DOI |
39 | Hou YN, Wu JC, Huang Q, et al (2009). Luteolin inhibits proliferation and affects the function of stimulated rat synovial fibroblasts. Cell Biol Int, 33, 135-47. DOI |
40 | Jemal A, Siegel R, Ward E, et al (2011). Cancer Stat CA Cancer J Clin, 61, 69-90. DOI |
41 | Kahlert S, Nuedling S, van Eickels M, et al (2000). Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem, 275, 18447-53. DOI ScienceOn |
42 | Kappel CC, Velez-Yanguas MC, Hirschfeld S, et al (1994). Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res, 54, 2803-7. |
![]() |